"目录号: HY-14302
GPCR/G Protein-
Salmeterol是长效β2肾上腺素受体激动剂，可作用于哮喘。
Adrenergic Receptor
相关产品
Isoprenaline hydrochloride-Norepinephrine bitartrate monohydrate-(R)-(-)-Phenylephrine hydrochloride-ICI 118,551 hydrochloride-Propranolol hydrochloride-L-Epinephrine-Ivabradine hydrochloride-Clonidine hydrochloride-Salmeterol xinafoate-Phentolamine mesylate-Yohimbine Hydrochloride-Perphenazine-Silodosin-Vilanterol trifenatate-Atipamezole hydrochloride-
生物活性
Description
Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.Target: beta2-Adrenergic ReceptorSalmeterol is a long-acting beta2-adrenergic receptor agonist drug that is prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). salmeterol also binds with very high affinity at a second site, termed the "exosite", and that this exosite contributes to the long duration of action of salmeterol [1].
Clinical Trial
NCT00102882
GlaxoSmithKline
Asthma
October 2004
Phase 4
NCT02558088
University of Copenhagen
Pharmacokinetics in Healthy Young Men
September 2014
Phase 4
NCT00595361
Brigham and Women's Hospital
Asthma
January 2008
NCT01271556
University of Milan
Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients-Chronic Obstructive Pulmonary Disease-Bronchodilator Agents-Salmeterol
December 2008
NCT01395849
GlaxoSmithKline
Respiratory Disorders
October 2007
NCT01536587
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
July 2012
Phase 4
NCT01395862
GlaxoSmithKline
Respiratory Disorders
November 2007
NCT00452348
GlaxoSmithKline
Asthma
May 2007
Phase 4
NCT01332409
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
August 2009
NCT00914901
Bispebjerg Hospital-Hormone Laboratory, Aker University Hospital, Oslo, Norway
Asthma
July 2009
Phase 4
NCT00736801
University of Rostock-GlaxoSmithKline
Allergic Asthma
September 2005
NCT01332357
GlaxoSmithKline
Asthma
June 2009
NCT00830505
University of Dundee
Asthma
February 2009
Phase 4
NCT01361984
University of California, Los Angeles-Sunovion
Chronic Obstructive Pulmonary Disease-COPD-Emphysema-Chronic Bronchitis
June 2011
Phase 4
NCT01555138
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
February 2012
Phase 4
NCT00525564
Laval University-GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
May 2006
Phase 4
NCT00655616
University of Dundee-Merck Sharp & Dohme Corp.
Asthma
August 2007
NCT01657487
Far Eastern Memorial Hospital-Research Ethics Review Committee
Percentage of Annual Acute Exacerbation-Quality of Life
April 2010
Phase 4
NCT00908362
University of Rostock-GlaxoSmithKline
Smoke-related Lung Diseases-Chronic Obstructive Pulmonary Disease
May 2009
Phase 1
NCT00567996
Novartis
Chronic Obstructive Pulmonary Disease (COPD)
November 2007
Phase 3
NCT02254187
Boehringer Ingelheim
Healthy
September 2005
Phase 1
NCT00364442
GlaxoSmithKline
Asthma
January 2005
Phase 1
NCT00422604
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
October 2006
Phase 2
NCT00950794
GlaxoSmithKline
Asthma-Bronchial Asthma
September 2003
Phase 4
NCT02254174
Boehringer Ingelheim
Healthy
March 2006
Phase 1
NCT00452699
GlaxoSmithKline
Asthma
May 2007
Phase 4
NCT00448435
GlaxoSmithKline
Bronchial Asthma
April 2007
Phase 3
NCT00741767
Northwestern University-GlaxoSmithKline
Chronic Obstructive Pulmonary Disease-Sleep Disorders
August 2008
NCT01860066
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
December 2013
Phase 3
NCT00864812
The Korean Academy of Tuberculosis and Respiratory Diseases-GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
March 2009
Phase 4
NCT02415179
Mahidol University
Asthma
May 2015
NCT01315249
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
March 2011
Phase 3
NCT02516592
Novartis Pharmaceuticals-Novartis
COPD
October 2015
Phase 4
NCT01231230
University of Miami-GlaxoSmithKline
Asthma
May 2007
NCT03060044
Orion Corporation, Orion Pharma
Asthma
July 2016
Phase 1
NCT02162485
Orion Corporation, Orion Pharma
Asthma
June 2014
Phase 1
NCT00821093
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease (COPD)
January 2009
Phase 3
NCT00197106
GlaxoSmithKline
Asthma
June 2005
Phase 4
NCT00346749
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
December 2006
Phase 4
NCT02649478
Roxane Laboratories-Vectura Limited
Asthma
August 2014
NCT01636076
Novartis Pharmaceuticals-Novartis
COPD
November 2012
Phase 2
NCT01709903
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
November 2012
Phase 3
NCT00144911
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
October 2004
Phase 4
NCT03158311
Novartis Pharmaceuticals-Novartis
Asthma
October 16, 2017
Phase 3
NCT00214019
University of Wisconsin, Madison-GlaxoSmithKline
Allergic Asthma
November 2003
NCT00441441
GlaxoSmithKline
Asthma
February 2007
Phase 3
NCT00449046
GlaxoSmithKline
Bronchial Asthma
March 2007
Phase 3
NCT02218762
GlaxoSmithKline
Asthma
October 2014
Phase 1
NCT00563381
Boehringer Ingelheim-Pfizer
Pulmonary Disease, Chronic Obstructive
January 2008
Phase 4
NCT01834885
Novartis Pharmaceuticals-Novartis
Chronic Obstructive Pulmonary Disease
December 2013
Phase 3
NCT01488773